Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more


  • Comment

VOL: 101, ISSUE: 50, PAGE NO: 32



- Oseltamivir.



- Tamiflu.



- Inhibits viral neuraminidase and therefore reduces replication of viruses in influenza A and B.



- Antiviral drugs - influenza.



- Postexposure prophylaxis for at-risk adults and adolescents who are not protected by influenza immunisation, and treatment of at-risk adults for whom medication can be started within 48 hours of close contact exposure, are recommended by the National Institute for Health and Clinical Excellence (NICE).



- NICE recommendations include prophylaxis in residential care homes, regardless of immunisation status, if commenced within 48 hours, when influenza-like illness is present in the establishment.



- Renal impairment.



- Pregnancy.



- Breastfeeding.



- Nausea.



- Vomiting.



- Abdominal pain.



- Dyspepsia.



- Diarrhoea.



- Headache.



- Fatigue.



- Insomnia.



- Dizziness.



- Conjunctivitis.



- Epistaxis.



- Rash.



- Hypersensitivity reactions.



- Hepatitis.



- Stevens-Johnson syndrome.



- Capsules.



- Suspension.



- For treatment to be most effective it should be started within a few hours of the onset of symptoms and continued for at least seven days (up to six weeks during an epidemic).



- NICE recommends that oseltamivir is not used for seasonal prophylaxis of influenza, postexposure prophylaxis or treatment in otherwise healthy individuals.



- Oseltamivir will not prevent the transmission of the influenza virus, therefore good hygiene and infection control practice should be maintained when in contact with infected individuals.



- The most effective method of preventing influenza infection is by annual immunisation and oseltamivir should not be seen as a substitute for vaccination.



- The Department of Health is procuring 14.6 million courses of oseltamivir as part of the UK’s preparation for an influenza pandemic.



- Advise patients to take a missed dose as soon as remembered. If it is two hours or less until the next dose, skip the missed dose and continue regular dosing schedule.



- Ensure patients are aware of the importance of continuing their medication, even if they start to feel better, until they have completed the course.



- Nurses should refer to manufacturer’s summary of product characteristics and to appropriate local guidelines.

  • Comment

Related files

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.